Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and c...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 11, 2017
|
| In: |
The lancet
Year: 2017, Jahrgang: 389, Heft: 10073, Pages: 1011-1024 |
| ISSN: | 1474-547X |
| DOI: | 10.1016/S0140-6736(16)32409-6 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/S0140-6736(16)32409-6 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0140673616324096 
|
| Verfasserangaben: | John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, Derek A O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R Izbicki, Gary William Middleton, Sebastian Cummins, Paul J Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting Ma, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W Büchler, for the European Study Group for Pancreatic Cancer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576104737 | ||
| 003 | DE-627 | ||
| 005 | 20220814154047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180606s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(16)32409-6 |2 doi | |
| 035 | |a (DE-627)1576104737 | ||
| 035 | |a (DE-576)506104737 | ||
| 035 | |a (DE-599)BSZ506104737 | ||
| 035 | |a (OCoLC)1341011061 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Neoptolemos, John P. |e VerfasserIn |0 (DE-588)172283302 |0 (DE-627)697192954 |0 (DE-576)133150879 |4 aut | |
| 245 | 1 | 0 | |a Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) |b a multicentre, open-label, randomised, phase 3 trial |c John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, Derek A O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R Izbicki, Gary William Middleton, Sebastian Cummins, Paul J Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting Ma, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W Büchler, for the European Study Group for Pancreatic Cancer |
| 264 | 1 | |c March 11, 2017 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 25 January 2017 | ||
| 500 | |a Gesehen am 06.06.2018 | ||
| 520 | |a The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer. | ||
| 700 | 1 | |a Hackert, Thilo |d 1971- |e VerfasserIn |0 (DE-588)122158512 |0 (DE-627)70579346X |0 (DE-576)182659208 |4 aut | |
| 700 | 1 | |a Büchler, Markus W. |d 1955- |e VerfasserIn |0 (DE-588)120893339 |0 (DE-627)080952526 |0 (DE-576)292434146 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet |d London [u.a.] : Elsevier, 1823 |g 389(2017), 10073, Seite 1011-1024 |h Online-Ressource |w (DE-627)270128484 |w (DE-600)1476593-7 |w (DE-576)078590159 |x 1474-547X |7 nnas |a Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) a multicentre, open-label, randomised, phase 3 trial |
| 773 | 1 | 8 | |g volume:389 |g year:2017 |g number:10073 |g pages:1011-1024 |g extent:14 |a Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) a multicentre, open-label, randomised, phase 3 trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(16)32409-6 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0140673616324096 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180606 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 120893339 |a Büchler, Markus W. |m 120893339:Büchler, Markus W. |d 910000 |d 910200 |e 910000PB120893339 |e 910200PB120893339 |k 0/910000/ |k 1/910000/910200/ |p 34 |y j | ||
| 998 | |g 122158512 |a Hackert, Thilo |m 122158512:Hackert, Thilo |d 910000 |d 910200 |e 910000PH122158512 |e 910200PH122158512 |k 0/910000/ |k 1/910000/910200/ |p 32 | ||
| 999 | |a KXP-PPN1576104737 |e 3011765774 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"John P.","family":"Neoptolemos","display":"Neoptolemos, John P."},{"display":"Hackert, Thilo","family":"Hackert","role":"aut","given":"Thilo"},{"family":"Büchler","role":"aut","given":"Markus W.","display":"Büchler, Markus W."}],"title":[{"title_sort":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4)","title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4)","subtitle":"a multicentre, open-label, randomised, phase 3 trial"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"14 S."}],"language":["eng"],"id":{"doi":["10.1016/S0140-6736(16)32409-6"],"eki":["1576104737"]},"origin":[{"dateIssuedDisp":"March 11, 2017","dateIssuedKey":"2017"}],"name":{"displayForm":["John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, Derek A O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R Izbicki, Gary William Middleton, Sebastian Cummins, Paul J Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting Ma, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W Büchler, for the European Study Group for Pancreatic Cancer"]},"recId":"1576104737","note":["Available online 25 January 2017","Gesehen am 06.06.2018"],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"The lancet <London>"},{"title":"London lancet"},{"title":"Lancet (British ed. Online)"}],"language":["eng"],"pubHistory":["1.1823 -"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"The lancet","title_sort":"lancet"}],"recId":"270128484","disp":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) a multicentre, open-label, randomised, phase 3 trialThe lancet","id":{"eki":["270128484"],"issn":["1474-547X"],"zdb":["1476593-7"]},"origin":[{"dateIssuedDisp":"1823-","dateIssuedKey":"1823","publisher":"Elsevier ; The Lancet Ltd.","publisherPlace":"London [u.a.] ; London"}],"part":{"volume":"389","pages":"1011-1024","text":"389(2017), 10073, Seite 1011-1024","extent":"14","year":"2017","issue":"10073"}}]} | ||
| SRT | |a NEOPTOLEMOCOMPARISON1120 | ||